Intravitreal aflibercept injection [IAI]

Phase 3

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Nonproliferative Diabetic Retinopathy

Clinical Trial

Last updated: 1/2/2026

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Homozygous Familial Hypercholesterolemia

Hypercholesterolemia

Melanoma

Non-Small Cell Lung Cancer

Follicular Lymphoma (FL)